Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15063 Results for "
Comparative receptor surface analysis
" in MedChemExpress (MCE) Product Catalog:
Products (15063)
15063 Results for "Comparative receptor surface analysis" in MCE Product Catalog:
Cat. No.: HY-P700213AF
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL1F10; MGC119832; Interleukin 1 Family Member 10; MGC119833; IL-1HY2; MGC11983; IL1-Theta; IL1HY2; IL-1F10; Interleukin-1 receptor Antagonist-Like FIL1 Theta; FKSG75; Interleukin 1 Family, Member 10 (Theta); IL-38; Interleukin 1 Family Member 10 (Theta)
Species:
Mouse
Source:
E. coli
Cat. No.: HY-P811887
Synonyms: RNF139; Ring Finger Protein 139; TRC8; HRCA1; RCA1; Translocation In Renal Carcinoma On Chromosome 8 Protein; Translocation In Renal Carcinoma, Chromosome 8; RING-Type E3 Ubiquitin Transferase RNF139; E3 Ubiquitin-Protein Ligase RNF139; Patched Related Protein Translocated In Renal Cancer; Multiple Membrane Spanning receptor TRC8; RING Finger Protein 139; EC 2.3.2.27
Cat. No.: HY-P811887A
Synonyms: RNF139; Ring Finger Protein 139; TRC8; HRCA1; RCA1; Translocation In Renal Carcinoma On Chromosome 8 Protein; Translocation In Renal Carcinoma, Chromosome 8; RING-Type E3 Ubiquitin Transferase RNF139; E3 Ubiquitin-Protein Ligase RNF139; Patched Related Protein Translocated In Renal Cancer; Multiple Membrane Spanning receptor TRC8; RING Finger Protein 139; EC 2.3.2.27
Cat. No.: HY-P83741
Synonyms: 17 1A antibody;
323/A3 antibody;
Adenocarcinoma associated antigen antibody;
Antigen identified by monoclonal antibody;
AUA1 antibody;
CD326 antibody;
Cell surface glycoprotein Trop 1 antibody;
CO17A antibody;
DIAR5 antibody;
EGP 2 antibody;
EGP antibody;
EGP2 antibody;
EGP314 antibody;
EGP40 antibody;
EPCAM antibody;
Epithelial cell adhesion molecule antibody;
ESA antibody;
GA733 1 antibody;
gp4 antibody;
hEGP 2 antibody;
hEGP314 antibody;
HNPCC8 antibody;
KS1/4 antibody;
KSA antibody;
Ly74 antibody;
M1S 1 antibody;
M1S2 antibody;
M4S1 antibody;
mEGP314 antibody;
MIC18 antibody;
MK 1 antibody;
Protein 289A antibody;
TACD1 antibody;
TACSTD1 antibody;
TROP1 antibody
Cat. No.: HY-P85607
Synonyms: Bag 1; BAG family molecular chaperone regulator 1; BAG-1; BAG1; BAG1_HUMAN; BCL 2 Associated Athanogene 1; BCL 2 associated athanogene; BCL 2 binding athanogene 1; Bcl-2-associated athanogene 1; BCL2 associated athanogene 1; BCL2 associated athanogene; Glucocorticoid receptor-associated protein RAP46; HAP1; Haptoglobin; RAP 46; RAP46.
Cat. No.: HY-P87146
Synonyms: HGNC:17793 antibody; V SNARE antibody; v-SNARE antibody; Vesicle associated soluble NSF attachment protein receptor antibody; Vesicle transport through interaction with t SNAREs 1B antibody; Vesicle transport through interaction with t SNAREs homolog 1B (yeast) antibody; Vesicle transport through interaction with t-SNAREs homolog 1B antibody; Vesicle transport v-SNARE protein Vti1-like 1 antibody; VTI1 antibody; VTI1 like antibody; HGNC:17793 antibody; V SNARE antibody; v-SNARE antibody; Vesicle associated soluble NSF attachment protein receptor antibody; Vesicle transport through interaction with t SNAREs 1B antibody; Vesicle transport through interaction with t SNAREs homolog 1B (yeast) antibody; Vesicle transport through interaction with t-SNAREs homolog 1B antibody; Vesicle transport v-SNARE protein Vti1-like 1 antibody; VTI1 antibody; VTI1 like antibody; Vti1 rp1 antibody; VTI1-LIKE antibody; Vti1-rp1 antibody; VTI1B antibody; VTI1B_HUMAN antibody; VTI1L antibody; VTI1L1 antibody; VTI2 antibody;
Cat. No.: HY-L170
258 compounds
An emerging drug design method is based on the secondary binding site effect, where small molecule drugs are designed to bind to secondary binding sites on target biomolecules rather than primary orthomorphic sites. Successful potential drugs (known as allosteric modulators) will be able to bind to allosteric sites and remotely alter (or modify) the conformation of the main orthosteric binding sites of biological targets. Allosteric modulators (AMs) are ligands of proteins that act through binding sites different from natural (orthosteric) ligand sites. AMs are relatively small, more lipophilic, and more rigid compounds. The binding efficacy of AMs with their targets is often slightly lower. AMs are divided into positive AMs (PAMs) and negative AMs (NAMs). AMs are ideal drug targets because they can fine-tune receptor activity while preserving the spatial and temporal signal transduction characteristics of endogenous ligands, resulting in fewer targeted side effects, improved subtype selectivity, and better promotion of biased signal transduction than normal ligands.
MCE designs a unique collection of 258 small allosteric modulators. It is a good tool to be used for research on metabolize, cancer and other diseases.
Cat. No.: HY-L166
1,751 compounds
Ion channel is a membrane-binding enzyme whose catalytic site is an ion conduction pore, which is opened and closed in response to specific environmental stimuli (voltage, ligand concentration, membrane tension, temperature, etc.). Ion channel provide pores for the passive diffusion of ions on the biofilm. Due to their high selectivity for ion, ion channel are generally classified as sodium (Na+ ), potassium (K+ ), calcium (Ca2+ ), chloride (Cl- ), and non-specific cation channel. Ion channel is an important contributor to cell signal transduction and homeostasis. In addition to electrical signal transduction, ion channel also have many functions: regulating vascular smooth muscle contraction, maintaining normal cell volume, regulating glandular secretion, protein kinase activation, etc. Therefore, dysfunction of ion channel can lead to many diseases, and its mechanism research is particularly important.
MCE designs a unique collection of 1,751 small molecules related to ion channel, mainly targeting Na+ channel, K+ channel, Ca2+ channel, GABA receptor, iGluR, etc. It is an essential tool for research of cardiovascular diseases, Nervous system diseases and other diseases.
Cat. No.: HY-P86740
Synonyms: ITGA 2; MGC11227; MHAM; MMAC 1; MMAC1; Bannayan Zonana; BZS a; Multiple hamartoma(Cowden syndrome); Mutated in Mutiple Advanced Cancers 1; Phosphatase and Tensin Homolog; Phosphatidylinositol 345 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN; Phosphatidylinositol 345 trisphosphate 3 phosphatase; Platelet antigen BR; PTEN 1; PTEN1; Tensin homolog; TEP 1; TEP1; VLA 2 receptor alpha Subunit.
Cat. No.: HY-P86740A
Synonyms: ITGA 2; MGC11227; MHAM; MMAC 1; MMAC1; Bannayan Zonana; BZS a; Multiple hamartoma(Cowden syndrome); Mutated in Mutiple Advanced Cancers 1; Phosphatase and Tensin Homolog; Phosphatidylinositol 345 trisphosphate 3 phosphatase and dual specificity protein phosphatase PTEN; Phosphatidylinositol 345 trisphosphate 3 phosphatase; Platelet antigen BR; PTEN 1; PTEN1; Tensin homolog; TEP 1; TEP1; VLA 2 receptor alpha Subunit.
Cat. No.: HY-P7322U
Purity: ≥ 95%, as determined by reducing SDS-PAGE.; ≥ 90%, as determined by MALS.
Synonyms: CD86; FUN-1; Prev. CD28LG2; B70; T-Lymphocyte Activation Antigen CD86; B-Lymphocyte Activation Antigen B7-2; B7.2; B-Lymphocyte Antigen B7-2; B7-2; CD86 Antigen; CD86 Antigen (CD28 Antigen Ligand 2, B7-2 Antigen); CD86 V6; CTLA-4 Counter-receptor B7.2; LAB72; Activation B7-2 Antigen; CD86 Molecule; BU63
Species:
Human
Source:
HEK293
Cat. No.: HY-L944
11028 compounds
MCE 18 stands for Medicinal Chemistry Evolution 2018. This metric was established based on structural data of 28,161 patented lead molecules, 1,370 marketed innovative drugs, and nearly 30,000 investigational candidates from preclinical to Phase III stages across 23 major global pharmaceutical companies from 1950 to 2018. After scaffold clustering analysis, a scoring model was constructed by integrating five three dimensional scaffold characteristics, including aromatic rings (AR), non aromatic heterocycles (NAR), chiral centers (CHIRAL), spirocycles (SPIRO), and the sp³ carbon ratio in cyclic and acyclic moieties, enabling quantitative assessment of molecular scaffold novelty and three dimensional complexity.
According to the score distribution of patented molecules, the top 25% of the original patent dataset was defined as the high novelty region. MCE 18 high scoring compounds selected based on this criterion can effectively avoid scaffold patent conflicts and intellectual property risks from the source. Molecules in this range typically feature a high sp³ carbon ratio, abundant chiral centers, spirocycles, and fused heterocycles with prominent three dimensional conformations. Their spatial properties allow precise matching to complex non traditional undruggable target pockets such as PPI interfaces and allosteric sites, making them ideal structural types for early stage screening of First in class drugs.
MCE‑18 Novelty Focused drug‑Like library strictly selects molecules from the aforementioned high scoring range, containing more than 10,000 premium drug like molecules with highly diverse scaffolds and rich 3D diversity. It can be used for high throughput screening of well established targets such as kinases, GPCRs, and proteases, and is especially suitable for hit identification in allosteric modulation, protein–protein interactions, and various undruggable orphan targets, fully supporting early stage drug discovery for cutting edge innovat
Cat. No.: HY-P73024
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: EFNA1; GMAN; Prev. TNFAIP4; Tumor Necrosis Factor Alpha-Induced Protein 4; Prev. EPLG1; TNF Alpha-Induced Protein 4; EPH-Related receptor Tyrosine Kinase Ligand 1; LERK-1; Ephrin-A1; Tumor Necrosis Factor, Alpha-Induced Protein 4; LERK1; Epididymis Secretory Sperm Binding Protein; Immediate Early Response Protein B61; Ligand Of Eph-Related Kinase 1; ECKLG; B61; Ephrin A1; Gastric Cancer Metastasis Associated Long Noncoding RNA
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P81184
Synonyms: Activation B7-1 antigen; B lymphocyte activation antigen B7; B7; B7-1; B7-1 antigen; BB1; CD28 antigen ligand 1; CD28LG; CD28LG1; CD80; CD80 antigen (CD28 antigen ligand 1, B7-1 antigen); CD80 antigen; CD80 molecule; CD80_HUMAN; Costimulatory factor CD80; costimulatory molecule variant IgV-CD80; CTLA-4 counter-receptor B7.1; LAB7; T-lymphocyte activation antigen CD80; CD80_RAT.
Cat. No.: HY-P82250
Synonyms: B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.
Cat. No.: HY-P85542
Synonyms: B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.
Cat. No.: HY-P704983
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD80; B-Lymphocyte Activation Antigen B7; Prev. CD28LG1; LAB7; Prev. CD28LG; BB1; T-Lymphocyte Activation Antigen CD80; B7; Activation B7-1 Antigen; Costimulatory Molecule Variant IgV-CD80; B7.1; Costimulatory Factor CD80; B7-1; CD80 Molecule; CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen); CD80 Antigen; CD80 Molecule; CTLA-4 Counter-receptor B7.1
Species:
Human
Source:
HEK293
Cat. No.: HY-P811992
Synonyms: KANK2; KN Motif And Ankyrin Repeat Domains 2; SIP; KIAA1518; ANKRD25; MXRA3; KN Motif And Ankyrin Repeat Domain-Containing Protein 2; Steroid receptor Coactivator Interacting Protein; Ankyrin Repeat Domain-Containing Protein 25; Matrix-Remodeling-Associated Protein 3; SRC1-Interacting Protein; SRC-Interacting Protein; Kidney Ankyrin Repeat-Containing Protein 2; Matrix-Remodelling Associated 3; SRC-1-Interacting Protein; Ankyrin Repeat Domain 25; NPHS16; PPKWH
Cat. No.: HY-P811992A
Synonyms: KANK2; KN Motif And Ankyrin Repeat Domains 2; SIP; KIAA1518; ANKRD25; MXRA3; KN Motif And Ankyrin Repeat Domain-Containing Protein 2; Steroid receptor Coactivator Interacting Protein; Ankyrin Repeat Domain-Containing Protein 25; Matrix-Remodeling-Associated Protein 3; SRC1-Interacting Protein; SRC-Interacting Protein; Kidney Ankyrin Repeat-Containing Protein 2; Matrix-Remodelling Associated 3; SRC-1-Interacting Protein; Ankyrin Repeat Domain 25; NPHS16; PPKWH
Cat. No.: HY-P706309
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: TNFSF9; Homolog Of Mouse 4-1BB-L; TNF Superfamily Member 9; receptor 4-1BB Ligand; 4-1BBL; CD137 Ligand; 4-1BB-L; 4-1BB Ligand; CD137L; Tumor Necrosis Factor (Ligand) Superfamily, Member 9, Isoform CRA_a; Tumor Necrosis Factor (Ligand) Superfamily, Member 9; Tumor Necrosis Factor Superfamily Member 9; Tumor Necrosis Factor Ligand Superfamily Member 9; TNLG5A; Tumor Necrosis Factor Ligand 5A
Species:
Human
Source:
HEK293
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
